SHENZHEN, China, June 24, 2025 /PRNewswire/ -- itel, a global leading smart life brand for everyone, proudly announced that its latest wireless earbuds, BudsNeo...
SHENZHEN, China, June 24, 2025 /PRNewswire/ -- itel, a global leading smart life brand for everyone, proudly announced that its latest wireless earbuds, BudsNeo...
TOMS RIVER, N.J., June 20, 2025 /PRNewswire/ -- In a supplement market saturated with empty promises and low-quality formulations, Pals Health emerges as a brand committed to...
CERES, Calif., June 23, 2025 /PRNewswire/ -- Casey Tedd, EVP of Classic Wines of California, announces new partnerships with four distinguished, family-owned California wine companies:...
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.
TIANSHUI, China, June 21, 2025 /PRNewswire/ -- To encourage exchange and cooperation in cultural heritage preservation, promote mutual learning among civilizations, and advance the...
NYSE American: UEC
CORPUS CHRISTI, Texas, June 20, 2025 /PRNewswire/ - Uranium Energy Corp (NYSE American: UEC) (the "Company" or "UEC") announces that it has acquired 170,000,000...
NYSE American: UEC
CORPUS CHRISTI, Texas, June 20, 2025 /CNW/ - Uranium Energy Corp (NYSE American: UEC) (the "Company" or "UEC") announces that it has acquired 170,000,000...
YELLOWKNIFE, NT, June 20, 2025 /CNW/ - The Canadian Coast Guard's annual Arctic summer operational season is underway. Through its new Arctic Strategy, the...
SEOUL, South Korea and NEW YORK, June 20, 2025 /CNW/ -- Parataxis Holdings LLC ("Parataxis Holdings"), an affiliate of Parataxis Capital Management LLC ("Parataxis Capital"...
SEOUL, South Korea and NEW YORK, June 20, 2025 /PRNewswire/ -- Parataxis Holdings LLC ("Parataxis Holdings"), an affiliate of Parataxis Capital Management LLC ("Parataxis Capital"...